Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review

被引：26
作者：
Diedhiou, Demba [1 ,2 ]
Cuny, Thomas [1 ]
Sarr, Anna [2 ]
Diop, Said Norou [2 ]
Klein, Marc [1 ]
Weryha, Georges [1 ]
机构：
[1] Lorraine Univ, Univ Hosp Ctr Nancy, Dept Endocrinol, Vandoeuvre Les Nancy, France
[2] Cheikh Anta Diop Univ, Univ Hosp Ctr Dakar, Dept Internal Med 2, Dakar, Senegal
来源：
ANNALES D ENDOCRINOLOGIE | 2015年 / 76卷 / 06期
关键词：
Osteoporosis; Denosumab; Fracture risk; Renal insufficiency; Safety; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; TURNOVER MARKERS; RISK REDUCTION; FRACTURE RISK; ALENDRONATE; THERAPY; MASS; PHASE-2;
D O I：
10.1016/j.ando.2015.10.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Denosumab is an anti-RANK ligand (RANKL) monoclonal antibody approved for the treatment of postmenopausal osteoporosis and prevention of skeletal metastasis complications. Administered subcutaneously every 6 months, it reduces the risk of vertebral fracture by 70% and of hip fracture by 40%. Its safety profile is acceptable. Denosumab may be used to treat patients with moderate to severe renal insufficiency. It has anti-fracture activity equivalent to that of zoledronic acid, but no residual effect, and no action at all beyond 6 months. In France, denosumab is reimbursed as a second-line treatment after a first attempt with bisphosphonate. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：650 / 657
页数：8
相关论文
共 50 条
  • [21] Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
    Chen, Yi
    Zhu, Jun
    Zhou, Yiqin
    Peng, Jinhui
    Wang, Bo
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [22] Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis
    Binkley, N.
    Orwoll, E.
    Chapurlat, R.
    Langdahl, B. L.
    Scott, B. B.
    Giezek, H.
    Santora, A. C.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (01) : 173 - 184
  • [23] Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis
    Diker-Cohen, Talia
    Rosenberg, Dana
    Avni, Tomer
    Shepshelovich, Daniel
    Tsvetov, Gloria
    Gafter-Gvili, Anat
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (05)
  • [24] Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
    Yanbeiy, Zeina A.
    Hansen, Karen E.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 2843 - 2852
  • [25] Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis
    Yang, Jia
    Guo, Xiaobo
    Cui, Zhongning
    Guo, Huikang
    Dong, Jia-Nan
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [26] Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
    Lewiecki, E. Michael
    DRUG HEALTHCARE AND PATIENT SAFETY, 2011, 3 : 79 - 91
  • [27] Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis
    Fontalis, Andreas
    Kenanidis, Eustathios
    Prousali, Efthymia
    Potoupnis, Michael
    Tsiridis, Eleftherios
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (04) : 413 - 428
  • [28] Osteoporosis in men: epidemiology and treatment with denosumab
    Sidlauskas, Kristel M.
    Sutton, Emily E.
    Biddle, Michael A.
    CLINICAL INTERVENTIONS IN AGING, 2014, 9 : 593 - 601
  • [29] Denosumab - a new option in the treatment of osteoporosis
    Franek, Edward
    ENDOKRYNOLOGIA POLSKA, 2011, 62 (01) : 79 - 83
  • [30] Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
    Yuan, Chuanjian
    Liang, Yanchen
    Zhu, Kai
    Xie, Wenpeng
    JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, 2023, 18 (01)
12345